- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment Considerations for MGMT-Unmethylated Glioblastoma
Authors
Keywords
Glioblastoma, Glioma, MGMT, Methylation, Temozolomide, Alkylating agents, Hypofractionation
Journal
Current Neurology and Neuroscience Reports
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-11-15
DOI
10.1007/s11910-014-0507-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
- (2014) Michael Weller et al. LANCET ONCOLOGY
- The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide
- (2014) E. L. Moen et al. MOLECULAR CANCER THERAPEUTICS
- MGMT testing—the challenges for biomarker-based glioma treatment
- (2014) Wolfgang Wick et al. Nature Reviews Neurology
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
- (2013) A. D. Norden et al. NEURO-ONCOLOGY
- Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation
- (2013) W. Wick et al. NEURO-ONCOLOGY
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
- (2011) Guido Reifenberger et al. INTERNATIONAL JOURNAL OF CANCER
- Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
- (2011) Jaime Gállego Pérez-Larraya et al. JOURNAL OF CLINICAL ONCOLOGY
- Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres
- (2010) D. Sciuscio et al. CLINICAL CANCER RESEARCH
- Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
- (2010) Roger Stupp et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma
- (2009) Alba A. Brandes et al. CANCER
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
- Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
- (2009) Sibille Everhard et al. NEURO-ONCOLOGY
- Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma
- (2008) Ilse Vlassenbroeck et al. JOURNAL OF MOLECULAR DIAGNOSTICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started